BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Scimera BioScience Release: New Product Created in South Florida May Help Millions Who Suffer From G.I. Side Effects of Antibiotics


4/3/2013 10:19:11 AM

MIAMI, FL--(Marketwired - April 03, 2013) -

Miami-based nutritional supplement maker Scimera BioScience® announced promising news for the 40 million Americans who suffer from the gastrointestinal side effects of antibiotics, also known as antibiotic-associated diarrhea or AAD. Scimera's probiotic formulation, Asprega ProPac, was created to address these side effects and comes in a novel 10-day package+. As a result, consumers can purchase a smaller, less expensive course of probiotics to last the typical duration of their antibiotic prescription.

ProPac, which uses the same complex blend of 11 probiotic strains and saccharomyces boulardii yeast found in Scimera's Asprega product, seeks to replace "good bacteria" that can be disturbed during antibiotic therapy. It is thought that this disturbance of gastrointestinal flora causes clinical symptoms of AAD.*

"We have seen significant evidence over the past half-dozen years that probiotics may reduce antibiotic-associated diarrhea for about 50 to 60% of patients who suffer from symptoms*," said South Florida physician Frederick Chaleff, M.D., founder and CEO of Scimera BioScience and one of the key players in formulating Asprega. "ProPac offers patients an opportunity to address the side effects caused by their antibiotics*+ -- and at a lower cost. ProPac costs less than half of full-size packages of competing probiotics."

At 20 billion CFUs (colony forming units), Asprega ProPac has more than double the potency of most probiotics. In addition, its delayed-release capsule delivers maximum effectivenesss in the digestive tract.

For information about Scimera BioScience and Asprega ProPac, visit www.scimera.com.

About Scimera BioScience

Scimera Bioscience® develops cutting-edge Bioceuticals that address cardiovascular, immune system, bone and joint, gastrointestinal, respiratory, prostate and a wide array of health issues. The Scimera team is comprised of Physicians, Pharmacists, Chemists, and Consumer Advocates with extensive clinical experience to produce science-based health solutions.

+These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

*Clinical research suggests use of probiotics may reduce onset of AAD. JAMA 2012, V307 #18


Contact:
Alex Madeja
The Weinbach Group, Inc.
(305) 668-0070



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES